Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy
Joint Authors
Saleem, Sameer
Alrifai, Taha
Ali, Faisal Shaukat
Ruiz, Diana Carolina Miranda
Rifai, Dana
Younas, Sundas
Qureshi, Faisal
Source
Case Reports in Oncological Medicine
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-11-04
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
Immune checkpoint inhibitors (ICPIs) are a breakthrough therapy in oncology and have been approved by the Food and Drug Administration for the treatment of several malignancies.
ICPIs have been reported to cause immune-mediated damage of islet cells leading to ICPI-induced type 1 diabetes mellitus (T1DM).
These reports described patients presenting with severe diabetic ketoacidosis (DKA).
We present a case of a 69-year-old Caucasian male with type 2 diabetes suffering from non-small cell lung cancer and undergoing treatment with pembrolizumab, an anti-programmed cell death protein-1 antibody, who presented to our emergency department with complaints of nausea, vomiting, polyuria, and polydipsia.
He was found to have high anion gap metabolic acidosis with ketosis and elevated blood glucose levels consistent with DKA.
Lab workup was consistent with T1DM.
Despite being on a tailored insulin regimen, his blood glucose remained elevated, necessitating the addition of metformin to his regimen which effectively controlled his blood glucose.
American Psychological Association (APA)
Alrifai, Taha& Ali, Faisal Shaukat& Saleem, Sameer& Ruiz, Diana Carolina Miranda& Rifai, Dana& Younas, Sundas…[et al.]. 2019. Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy. Case Reports in Oncological Medicine،Vol. 2019, no. 2019, pp.1-3.
https://search.emarefa.net/detail/BIM-1142179
Modern Language Association (MLA)
Alrifai, Taha…[et al.]. Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy. Case Reports in Oncological Medicine No. 2019 (2019), pp.1-3.
https://search.emarefa.net/detail/BIM-1142179
American Medical Association (AMA)
Alrifai, Taha& Ali, Faisal Shaukat& Saleem, Sameer& Ruiz, Diana Carolina Miranda& Rifai, Dana& Younas, Sundas…[et al.]. Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy. Case Reports in Oncological Medicine. 2019. Vol. 2019, no. 2019, pp.1-3.
https://search.emarefa.net/detail/BIM-1142179
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1142179